When knee cartilage can be treated without an operation

Not every damaged knee requires an operation. For patients with a focal, contained cartilage defect — typically ICRS Grade III or IV — in a joint that is otherwise well preserved, an injectable scaffold is a genuine non-surgical pathway rather than a distant possibility.

The key word is focal. Diffuse cartilage loss across a compartment, or end-stage osteoarthritis, falls outside the scope of any regenerative approach; in those cases the conversation shifts towards joint preservation surgery or, eventually, replacement. The target for injectable scaffold treatment is a discrete lesion, generally up to around 3 cm² in area (extendable to 6 cm² in certain cases), with healthy surrounding cartilage and bone.

ChondroFiller injection — a CE-marked injectable collagen scaffold — represents the current-service option in this category. It is delivered as an ultrasound-guided outpatient procedure; the section that follows covers how it works.

It is worth being clear about what injectable scaffold treatment is not. Hyaluronic acid viscosupplementation and platelet-rich plasma (PRP) injections are established, widely used treatments, but they primarily address pain and joint lubrication rather than stimulating structural repair of the defect itself — a meaningfully different category.

Beyond defect size, suitability depends on several factors: age, body-weight load, lower-limb alignment, meniscal integrity, and activity expectations all influence whether an injectable or surgical route is the more appropriate route. A specialist assessment is needed to determine which pathway applies.

How the ChondroFiller injection works

The mechanism behind ChondroFiller injection is easier to follow than it might initially appear. ChondroFiller is a purified Type I collagen gel — acellular, meaning it contains no living cells of its own. Injected under ultrasound guidance directly into the cartilage defect, the gel conforms to the lesion's shape as it firms up in place, filling irregular contours that a rigid, pre-formed implant cannot easily match — a practical advantage noted in the published literature on injectable versus solid scaffold formats.

Once settled, the collagen matrix acts as a structured scaffold that the body's own progenitor cells migrate into and begin to populate. This is the principle of matrix-induced chondrogenesis: rather than introducing donor cells or replacing tissue artificially, the scaffold guides the patient's own repair biology. Progenitor cells are recruited to the site, proliferate within the matrix, and, under the right conditions, begin producing cartilage-like tissue.

In published clinical series, knee outcomes following ChondroFiller injection have shown IKDC score improvements of approximately 30 points — a clinically meaningful shift in patient-reported function. MOCART scores, which assess cartilage fill and integration on MRI, have ranged from 70 to 87 in reported cases, indicating good structural fill at the treated site. These figures represent a realistic benchmark rather than a guarantee; individual results are shaped by defect characteristics, overall joint health, and rehabilitation adherence.

The procedure does not require an operating theatre. Patients attend as outpatients, and the injection is image-guided to ensure accurate placement within the defect.

Why cartilage doesn't heal on its own

Cartilage is unusual tissue. Unlike bone or muscle, articular cartilage has no direct blood supply — it draws nutrients from the synovial fluid bathing the joint surface. This avascular nature underpins its most clinically significant property: almost no capacity for self-repair. Chondrocytes, the cells responsible for maintaining the cartilage matrix, divide extremely slowly and cannot migrate to a damage site the way other repair cells can.

When a defect does form, the body fills it not with native cartilage but with fibrocartilage — a scar-like tissue produced by marrow cells that rise through the damaged subchondral bone. Fibrocartilage lacks the organised collagen architecture of hyaline cartilage and tends to break down under repetitive load, which is why cartilage injuries exceeding roughly 1 cm in area may worsen progressively without active treatment rather than stabilising on their own.

ICRS grading (I–IV) describes lesion depth: Grade I is surface softening; Grade IV is full-thickness loss that exposes bone beneath. Grade III and IV focal defects represent the primary territory for active repair rather than symptom management alone — and the biological conditions of a contained focal lesion (healthy surrounding cartilage, intact subchondral bone) are precisely what distinguish it from diffuse osteoarthritis, where no repair strategy has a viable substrate to work with.

Defect size, depth, location, and the health of the bone beneath together determine which repair approach is biomechanically realistic — and that framework is what makes the injectable versus surgical comparison meaningful.

Surgical repair options and what they involve

Surgical intervention for knee cartilage spans a spectrum from relatively straightforward marrow stimulation to demanding two-stage cell therapies — and the differences in complexity, evidence quality, and defect suitability are considerable.

Microfracture has historically been the first procedure reached for in small focal defects: an arthroscopic awl creates perforations in the subchondral bone, allowing marrow cells to rise and form repair tissue. That tissue is fibrocartilage rather than hyaline cartilage, and clinical evidence shows measurable deterioration at two to three years. Repeated perforation of the subchondral bone plate can also narrow the options available for any future repair — a limitation that has driven interest in more sophisticated single-stage approaches.

AMIC (autologous matrix-induced chondrogenesis) is one such bridge technique: it combines marrow stimulation with immediate placement of a collagen scaffold membrane over the prepared defect, aiming to stabilise the clot and improve tissue quality without requiring a second operation or laboratory cell culture.

ACI and MACI are two-stage, cell-based procedures. At the first arthroscopy, a small cartilage biopsy is harvested; the patient's own chondrocytes are then cultured over four to six weeks before reimplantation at a second procedure. Published series for ACI cite long-term success rates of around 80–90%, though outcomes are reported to be less favourable where prior marrow-stimulation procedures have already been performed. MACI seeds those cultured cells onto a Type I/III collagen membrane, reducing some technical challenges of the earlier generation. Both techniques typically suit defects in the 2–10 cm² range and are resource-intensive by design.

OATS and mosaicplasty transfer healthy osteochondral plugs from a lower-load area of the same joint to fill the defect — single-stage, and well matched to lesions of roughly 1–2 cm² (mosaicplasty can extend to approximately 4 cm²). Donor-site morbidity remains a meaningful consideration when weighing this option.

Osteochondral allograft (OCA) applies the same principle using donor tissue, making it appropriate for larger or post-traumatic defects where autograft is insufficient. It is single-stage but depends on tissue availability.

Across all these techniques, defect preparation — stable vertical borders, precise sizing, and technically exacting implantation — makes the operative process considerably more involved than an outpatient injection pathway, with rehabilitation programmes that reflect that complexity.

What the evidence shows when outcomes are compared

The clearest direct comparison available comes from a 2023 systematic review by Seewoonarain and colleagues, which found scaffold-augmented repair procedures superior to microfracture on patient-reported outcomes at two years — but equivalent at five years. That convergence deserves careful reading: it does not mean the two approaches are interchangeable, because they address different defect sizes and suit different patient profiles. A short-term advantage that normalises by year five may also reflect the known fibrocartilage breakdown pattern rather than genuine parity in tissue quality.

For larger focal defects, ACI's evidence base extends beyond nine years of follow-up, making it one of the most mature datasets in cartilage restoration. That depth of follow-up is not yet matched by injectable scaffold techniques, which are currently supported by promising mid-term data rather than decade-long series.

No large randomised controlled trial has directly compared a non-arthroscopic injectable scaffold to surgical repair in humans — which means individual techniques should be evaluated on their own evidence rather than by extrapolated comparison. Next-generation injectable hydrogels show compelling signals in animal models, including complete regeneration within twelve weeks in rabbit OA studies, but those findings are preclinical proof-of-concept and do not yet alter clinical decision-making pathways.

Across every technique discussed in this article, patient selection is the dominant moderator of outcome. A 1.5 cm² contained focal defect in an aligned knee with an intact meniscus sits in a fundamentally different position to a larger post-traumatic lesion with concurrent mechanical problems. Defect size, age, alignment, and meniscal status together determine which evidence base is actually applicable — and no comparative dataset substitutes for that individual clinical assessment.

Getting the right assessment and finding a specialist

Three questions are worth taking into any cartilage consultation: What grade and size is the defect, and what does imaging show about the surrounding tissue? Am I a candidate for an injectable scaffold approach, or does the defect require a surgical pathway? What does rehabilitation involve, and how does that fit with my activity level and commitments?

A full assessment typically combines weight-bearing X-rays — to evaluate joint-space narrowing and alignment — with MRI to characterise defect depth, subchondral bone status, and lesion boundaries. Clinical examination should also cover meniscal integrity and ligament stability. Where compartmental loading is uneven, an alignment correction procedure may be worth discussing alongside any cartilage repair plan, since offloading the affected compartment can influence long-term outcomes whichever repair route is chosen.

Search MSK lists knee cartilage specialists across the UK; filtering by region and specialty helps identify practitioners who hold experience across both injectable and surgical options rather than defaulting to a single pathway.

The most reliable sign of a thorough assessment is that the specialist has taken a full history — covering prior treatments, alignment, meniscal status, and activity demands — before making any recommendation. A practitioner who reaches for a solution before completing that picture is worth approaching with caution.